Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1356723 | 0.85 | HTR6 (0.68) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL1356485 | 0.84 | HTR6 (0.74) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3202003 | 0.81 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL1356234 | 0.78 | HTR6 (0.76) | HTR6 | |
| Hydrochloric Acid SCHEMBL1356229 | 0.77 | HTR6 (0.57) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3206031 | 0.77 | HTR6 (0.76) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3205319 | 0.77 | HTR6 (0.80) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL3201677 | 0.77 | HTR6 (1.00) | HTR6CYP3A4CYP2D6 | |
| SCHEMBL1356742 | 0.76 | HTR6 (0.69) | HTR6 | |
| SCHEMBL3205550 | 0.75 | HTR6 (0.77) | HTR6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318725-B2 | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-11-27 | — | — | US | claimed |
| US-20110281849-A1 | Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-11-17 | — | — | US | claimed |
| WO-2010032257-A1 | ARYL INDOLYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| US-8318725-B2 | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-11-27 | — | — | US | disclosed |
| US-20110281849-A1 | Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-11-17 | — | — | US | disclosed |
| WO-2010032257-A1 | ARYL INDOLYL SULFONAMIDE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281849-A1 | Aryl Indolyl Sulfonamide Compounds and Their Use as 5-HT6 Ligands | HTR6, HTR1A, HTR2C | HTR6 1/4885CYP3A4 137/4885CYP2D6 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.